CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
Published on August 23, 2019
Know
Labs, Inc.
August
23, 2019
Mr.
David Burton, Accounting Branch Chief
Securities
Exchange Commission
Division
of Corporation Finance
Office
of Electronics and Machinery
1100
F Street N.E.
Washington, D.C. 20549
Re:
|
Know Labs, Inc.
|
|
Registration Statement on Form S-1
|
|
Filed May 30, 2019
|
|
File No. 333-231829
|
Dear
Mr. Burton,
Reference
is made to the Staff’s comment letter dated July 31, 2019
(the “Staff’s Letter”) to Know Labs, Inc. (the
“registrant” or “Company”). The registrant
hereby submits the following responses to the comments contained in
the Staff’s Letter with respect to the registrant’s
Registration Statement on Form S-1 filed with the SEC on May 30,
2019.
For
convenience of reference, each comment contained in the
Staff’s Letter is reprinted below, numbered to correspond
with the paragraph numbers assigned in the Staff’s Letter,
and is followed by the corresponding response of the registrant.
These comments have been made in response to the Staff’s
comments.
Registration Statement on Form S-1 filed May 30, 2019
Fee table, page i
1.
We note your
response to prior comment 2 and Exhibit A to your response. Given
that it appears that you are seeking to register the resale of
common shares, not the exercise of warrants or the conversion of
the preferred stock, it is unclear why your reliance on Rule 457(g)
is appropriate. Please clarify or revise as appropriate. Also: show
us how you calculated the "Proposed Maximum Aggregate Offering
Price" and "Amount of Registration Fee" for the shares of common
stock underlying the interest on the convertible notes; and tell us
how you determined the number of shares issuable upon exercise of
the Series F Preferred Warrants, given your disclosure on pages
32-33 regarding the number of warrants issued.
Response. The registration includes the registration of
resale of common shares underlying the notes, warrants and
preferred stock. We have revised our filing accordingly as set
forth in Exhibit A attached hereto and incorporated herein
by reference to remove reference to 457(g) in agreeance with the
Staff’s letter.
Further,
the "Proposed Maximum Aggregate Offering Price" and "Amount of
Registration Fee" for the shares of common stock underlying the
interest on the convertible notes was calculated by multiplying the
principal of the 8% Unsubordinated Convertible Notes ($2,242,515)
by the interest rate (8%) for the one year maturity of the note
bring the total interest to $339,401. The total interest was
multiplied by closing average ($1.53). We recognize there was an
error in the amount of shares to be registered underlying the
interest in and the proposed maximum offering price;
500
Union St. #810 Seattle WA 98101
Knowlabs.co
The fee
table has been revised it as follows:
Title of Each Class
|
|
Proposed
Maximum
|
Proposed
Maximum
|
|
of Securities to
|
Amount to be
|
Offering
|
Aggregate
|
Amount of
|
be Registered
|
Registered (1)
|
Price Per
Unit
|
Offering Price
(2)
|
Registration Fee
|
Common
Stock, $0.001 par value per share, underlying the
Interest
|
|
|
|
|
of
8% Unsubordinated Convertible Notes (3)(4)
|
339,401
|
1.53
|
519,294
|
62.94
|
With
respect to the number of shares issuable upon exercise of the
Series F Preferred Warrants (“Series F Warrants”),
given our disclosure on pages 32-33 regarding the number of
warrants issued. The Series F Preferred Warrants were calculated
based on the number of shares issuable upon the exercise of the
Series F Preferred Warrants multiplied by the funds the Registrant
will receive upon the exercise of the Series F Preferred
Warrants.
The
Registrant issued the following Series F warrants:
Selling Security Holders, page 30
2.
Please expand your
response to the second bullet point of prior comment 3 to address
the common stock issuable upon exercise of the Series F Preferred
Warrants.
Response. We are registering 3,984,000 shares of common stock issuable upon conversion of
outstanding Series F Warrants that were previously issued to one of
the Selling Shareholders in connection with Preferred Stock and
Warrant Purchase Agreement dated November 10, 2016 (the
“Purchase Agreement”). The Series F Warrants were
originally issued at an exercise price of $0.80, a slight discount
to market, however, due to certain protective provisions in the
Purchase Agreement, if certain securities of the Company were
issued at a price lower than $0.80 then the exercise price of the
Series F Warrants was to be adjusted downwards to match resulting
in a reduced exercise price of $0.25.
3.
Please disclose the
substance of your response to the fourth bullet point of prior
comment 3. Also disclose, if true, that all securities offered by
an affiliate of a broker-dealer were purchased by the seller in the
ordinary course of business, and, at the time of the purchase of
the securities to be resold, the seller had no agreements or
understandings, directly or indirectly, with any person to
distribute the securities.
500
Union St. #810 Seattle WA 98101
Knowlabs.co
Response. All securities offered by the Broker-Dealer
Parties were received as compensation for underwriting activities
and were validly earned pursuant to their agreement with the
Company dated November 6, 2018 (the “Agreement”).
Pursuant to the Agreement, which is attached hereto as Exhibit B
and will be filed as an exhibit to Form S-1, Boustead Securities,
LLC a FINRA member, acted as our exclusive placement agent. They
received a 8% cash fee and 8% in warrants which are exercisable for
5 years at an exercise price of $1.20. All securities offered by an
affiliate of a broker-dealer were acquired by the seller in the
ordinary course of business, and, at the time of the purchase of
the securities to be resold, the seller had no agreements or
understandings, directly or indirectly, with any person to
distribute the securities.
4.
We note your
response to the eighth bullet point of prior comment 3. Please
ensure that the number of shares registered for sale in the fee
table is consistent with the shares listed in "Selling Security
Holders." We note in this regard that the "Grand Total" in column
(c) does not appear to reconcile to the proposed revisions to the
fee table.
Response. We have
revised the Selling Security Holders table, Grand Total in column C
to reconcile with the revisions to the fee table. We have included
a copy of the revised table as Exhibit B attached hereto and
incorporated herein by reference.
5.
We note from your
response to the tenth bullet point of prior comment 3 that the
company is not aware of any short positions held by any of the
selling stockholders. Please clarify whether that response was
based on information obtained from the Selling
Shareholders.
Response. The Company’s
response that is not aware of any short positions is based on its
reliance upon the contractual representations of the Selling
Shareholders as set forth in the Registration Rights Agreements
provided by each of the Selling Shareholders, a copy of which was
filed with the Registration Statement as Exhibit 10.33, which,
includes but is not limited to the following
representations:
“Company
has advised each Selling Shareholder that it is the view of the
Commission that it may not use shares registered on the
Registration Statement to cover short sales of Common Stock made
prior to the date on which the Registration Statement is declared
effective by the Commission, in accordance with 1997 Securities and
Exchange Commission Manual of Publicly Available Telephone
Interpretations Section A.65. If a Selling Shareholder uses the
prospectus for any sale of the Common Stock, it will be subject to
the prospectus delivery requirements of the Securities Act. The
Selling Shareholders will be responsible to comply with the
applicable provisions of the Securities Act and Exchange Act, and
the rules and regulations thereunder promulgated, including,
without limitation, Regulation M, as applicable to such Selling
Shareholders in connection with resales of their respective shares
under the Registration Statement.”
6.
Please expand your
response to prior comment 3 to provide us your analysis supporting
your conclusion regarding why your agreements with Boustead
Securities need not be filed as exhibits to your registration
statement.
Response. We do not disagree
and have filed a copy of the agreement with Boustead Securities as
Exhibit B, attached hereto and incorporated herein by reference,
and will file the same as an exhibit to our Form S-1
amendment.
7.
From your response
to prior comment 3, it appears that you do not intend to use cash
to repay the principal and interest under the note. It therefore
remains unclear whether in substance the transaction is a primary
offering of your common stock. Please expand your response, citing
all authority on which you rely, or revise your registration
statement as appropriate.
Response. The Company
respectfully submits that (i) the offering to be registered
pursuant to the Registration Statement is a valid secondary
offering and may be registered as contemplated by the Registration
Statement, and (ii) the Selling Security Holders are not
“underwriters” within the meaning of Section 2(a)(11)
of the Securities Act of 1933, as amended (the
“Securities
Act”).
500
Union St. #810 Seattle WA 98101
Knowlabs.co
Rule 415 Analysis
The
Staff has previously recognized the complexity of the analysis of
certain transactions under Rule 415 and has set forth a detailed
analysis of the relevant factors that should be examined in its
Compliance and Disclosure Interpretation (the “C&DI”)
612.09:
“It is
important to identify whether a purported secondary offering is
really a primary offering, i.e., the selling shareholders are
actually underwriters selling on behalf of an issuer. Underwriter
status may involve additional disclosure, including an
acknowledgment of the seller’s prospectus delivery
requirements ... The question of whether an offering styled a
secondary one is really on behalf of the issuer is a difficult
factual one, not merely a question of who receives the
proceeds. Consideration
should be given to how long the selling shareholders have held the
shares, the circumstances under which they received them, their
relationship to the issuer, the amount of shares involved, whether
the sellers are in the business of underwriting securities, and
finally, whether under all the circumstances it appears that the
seller is acting as a conduit for the issuer.” (emphasis added)
As
C&DI 612.09 indicates, the question is a
“difficult” and “factual” one that involves
an analysis of many factors and “all the
circumstances.” Each of the relevant factors listed in
C&DI 612.09 is discussed below. The Company respectfully
submits that, based on a proper consideration of all of these
factors, the Registration Statement relates to a valid secondary
offering and that all of the shares of Common Stock can be
registered for resale on behalf of the Selling Shareholders
pursuant to Rule 415.
How Long the Selling Shareholders Have Held the Shares
The
Company advises the Staff that the Selling Shareholders have now
held the securities, pursuant to which the underlying common stock
is being registered, as follows:
(i) all
securities associated with the offering and sale of the 8%
Unsubordinated Convertible Notes, including common stock underlying
the Principal and Interest of the Notes, the Warrants and Placement
Agent Warrants (collectively the “Note Offering”),
which were sold in a series of closings
between February 15, 2019 and May 28, 2019, have been held
for between nearly three (3) and five (5) months, and have not yet
effected any conversion of such securities into shares of Common
Stock.
(i) The
Selling Shareholder of the Series D Preferred Stock and Series F
Warrants (collectively the “Preferred”) acquired the
securities pursuant to the Preferred
Stock and Warrant Purchase Agreement dated November 10, 2016 and
has held the securities for nearly 3 years (the “Preferred
Offering”).
Presumably,
the longer securities are held, the less likely it is that the
Selling Shareholders are acting as a mere conduit for the issuer.
Since the time the Selling Shareholders acquired the securities,
they have had market risk. Moreover, there is currently no market
for the Preferred Stock nor the Notes or Warrants, and one is not
anticipated to develop. In addition, the earliest that the
investors or the Company can convert the Preferred and Notes into
Common Shares, for which there is a readily available market
(albeit, as discussed below, one with limited trading volume), is
one year after issuance (although the Notes could be mandatorily
converted earlier if the Company consummates Qualified Financing).
In addition, each Selling Shareholder made specific representations
to the Company that such investor was acquiring the respective
Notes and Preferred in the ordinary course of business for such
Selling Shareholders’ own account and not with a view
towards, or for resale in connection with, the public sale or
distribution thereof. None of the Selling Shareholders’ has
sold any of the Preferred nor Notes, and there is no evidence to
suggest that the representations made by the Selling
Shareholders’ are false. The fact that the Common Stock is
now being registered for resale is not evidence that the Selling
Shareholders desire to effect an immediate distribution, which in
fact the Selling Shareholders are not able to do given that the
Preferred Shares are not yet convertible into Common
Shares.
In
C&DI 116.19, the Staff codified its “PIPEs”
interpretation, which contemplates that a valid secondary offering
could occur immediately following the closing of a PIPE
transaction. C&DI 116.19 provides in relevant
part:
500
Union St. #810 Seattle WA 98101
Knowlabs.co
In
a PIPE transaction, a company will be permitted to register the
resale of securities prior to their issuance if the company has
completed a Section 4(2)-exempt sale of the securities (or in
the case of convertible securities, of the convertible security
itself) to the investor, and the investor is at market risk at the
time of filing of the resale registration statement….The
closing of the private placement of the unissued securities must
occur within a short time after the effectiveness of the resale
registration statement.
Furthermore,
it is important to note that C&DI 139.13 provides that no
minimum holding period is required where a company has completed a
private transaction of all of the securities it is registering and
the investor is at market risk at the time of filing of the resale
registration statement. The Company is not aware that the Staff has
taken the position that the period of time elapsing between closing
and registration has raised concerns about whether the offering is
a valid secondary offering. In fact, the Company believes that such
concerns would be inconsistent with C&DI 116.19. Because no
holding period is required for a PIPE transaction to be a valid
secondary offering, the period that has already elapsed since the
signing of the Purchase Agreements is substantially longer than the
holding period required by the Staff for valid PIPE transactions.
This concept comports with longstanding custom and practice in the
PIPEs marketplace.
The Circumstances under Which They Received the Shares
The
Company respectfully submits that registration for resale of the
shares of Common Stock issuable upon conversion of the Note
Offering should not equate to intent to distribute by Selling
Shareholders. The securities comprising the Note Offering were
issued pursuant to the Form of Securities Purchase Agreement,
Subscription Agreement, Convertible Note, Warrant, Subordination
Agreement, and registration Rights Agreement, were filed as
Exhibits 10.28-10.33 to the registrants S-1 filed May 30, 2019
(collectively the “Note Offering Purchase Agreements”).
The Preferred were issued pursuant to the Form of Preferred Stock
and Warrant Purchase Agreement, Registration Rights Agreement and
Form of Warrant, which were filed as Exhibits 10.1-10.3 to the
registrants S-1 filed May 30, 2019 (the “Preferred Purchase
Agreement”, and collectively with the Note Offering Purchase
Agreements, the “Purchase Agreements”).
The
securities acquired pursuant to the Purchase Agreements were issued
pursuant to
the exemption from registration provided by Section 4(a)(2) of
the Securities Act and/or Rule 506 of Regulation D promulgated
thereunder. Accordingly, the securities held by the Selling
Shareholders are, and at all times have been, restricted securities
that could not have been, and may not be, offered or sold in the
United States absent registration or an applicable exemption from
the registration requirements of the Securities Act. In the
Purchase Agreements, the Selling Shareholders made specific
representations to the Company that they were purchasing the
securities for their own accounts and not with a view to the resale
or distribution thereof, and that they had no present intention of
selling or otherwise distributing such securities. In addition,
each of the Selling Shareholders represented that it had made its
own independent decision to purchase securities in the private
placement. The Company is not aware of any evidence that would
indicate that these specific representations were
false.
No
Selling Shareholder, by virtue of the Note Offering and Preferred
Offering, has any other subscription rights to obtain additional
Common Stock shares. All of the Selling Shareholders were, have
continued to be, and will likely continue to be for some time, at
market risk with respect to their Notes and Preferred and the
Common Stock issuable upon conversion thereof.
In most PIPE transactions, including the Note
Offering and Preferred Offering, a registration statement is
required to be filed shortly after closing (typically 30 to 90
days) and declared effective shortly thereafter. Although the
Selling Shareholders bargained for registration rights as part of
the Note Offering and Preferred Offering, registration rights, in
and of themselves, do not evidence intent on the part of the
Selling Shareholder to sell the securities. The Company notes that
there are many reasons why investors prefer to have their
securities registered other than to effect an immediate sale,
including, but not limited to: (i) some private investment
funds are required to mark their portfolios to market and if
portfolio securities are not registered, such investors are
required to mark down the book value of those securities to reflect
an illiquidity discount and (ii) not registering the
securities would prevent investors from taking advantage of market
opportunities or from liquidating their investment if there is a
fundamental shift in their original investment determination about
the Company. In addition, some of
the Selling Shareholders are fiduciaries for their
trusts/beneficiaries; as a result, such Selling Shareholders have a
duty to act prudently. Accordingly, the Company understands that
the Selling Shareholders wish to have their securities in a more
liquid form, whereas not registering the securities could prevent
them from taking advantage of market opportunities or from
liquidating their investment if there is a fundamental shift in
their investment judgment about the Company.
500
Union St. #810 Seattle WA 98101
Knowlabs.co
There
is no evidence that a distribution would occur if the Registration
Statement is declared effective. Under the Commission’s own
rules, a distribution requires “special selling
efforts”. Rule 100(b) of Regulation M defines a
“distribution” as “an offering of securities,
whether or not subject to registration under the Securities Act,
that is distinguished from ordinary trading transactions by the
magnitude of the offering and the presence of special selling
efforts and selling methods.”
Accordingly,
the mere size of a potential offering does not make a proposed sale
a “distribution.” Special selling efforts and selling
methods must be employed before an offering can constitute a
distribution. In this case, there is no evidence that any special
selling efforts or selling methods have or would take place if all
of the Common Shares issuable upon conversion of the Preferred and
Note Offerings and covered by the Registration Statement were
registered. To the Company’s knowledge, no Selling
Shareholder has any agreements or understandings, directly or
indirectly, with any person to distribute its securities, nor is
there any evidence that any of the Selling Shareholders have
conducted any road shows or taken any other actions to condition or
“prime” the market for their Shares. To do so would
violate the detailed representations made by them in the Purchase
Agreements.
The
circumstances of the Note and Preferred Offerings underscore that
it would be virtually impossible for the Selling Shareholders to
effect an illegal distribution even if they desired to do so
because the existing trading market for the Common Stock could not
absorb all of the Common Stock that may be issued to the Investors
upon conversion. According to the website Yahoo! Finance, the
three-month average daily trading volume of the Common Shares on
the OTCQB as of August 19, 2019 was approximately 13.99k shares. As
a result, it would take the Selling Shareholders nearly two years
to sell all of Common Stock shares subject to the Registration
Statement assuming no one else sold a single share. Furthermore,
the Selling Stockholder owning the Preferred Stock and warrants is
subject to a 4.99% blocker and as such may be even more limited in
the ability to sell the Common Stock shares subject to the
Registration Statement. In these circumstances, it is not credible
to conclude that the Selling Shareholder have purchased the
securities for the purpose of making a distribution. In this
situation, which is common in many PIPE transactions, the concept
that the Selling Shareholders have “freely tradable”
Shares is more theoretical than real. For all practical purposes,
the Investors are largely locked into their investments for a
significant period of time, regardless whether the common stock
underlying their securities are registered.
Selling Shareholders’ Relationship to the
Company
As disclosed in the Registration Statement, the
Selling Shareholders had no relationship with the Company prior to
its investment in the Notes Offering, with the exception of Clayton
Struve, who has invested in the past and is the sole Selling
Shareholder under the Preferred Offering. The Selling Shareholders
have no current relationship other than as a passive investor
holding the securities that have been issued to it.
None of the
Selling Shareholders are an affiliate of the Company. The Selling
Shareholders are not represented on the board of directors of the
Company, and the Selling Shareholders have no contractual rights to
control or otherwise influence the conduct of the Company’s
business and operations.
In
investor questionnaires delivered by the investors to the Company
in connection with the Purchase Agreements, each of the Investors
represented that it was not a broker-dealer registered with the
Commission. A handful of the Selling Shareholders are registered
brokers who received their warrants as consideration for services
rendered in the Notes Offering. As discussed above, each of the
Selling Shareholders also represented and warranted in the Purchase
Agreements that the securities being acquired by it were being
acquired for such Investor’s own account, not as nominee or
agent, and not with a view to the resale or distribution of any of
such securities in violation of the Securities Act. The Notes
Offering and Preferred Offering was negotiated at arm’s
length, with each of the Selling Shareholders incurring all of the
economic and market risk attendant to this type of
transaction.
In
fact, the Selling Shareholders are responsible for paying any
broker-dealer fees or underwriting discounts or commissions
directly to any broker-dealers they engage to assist in selling any
of the Company’s securities. The Selling Shareholders will
retain all proceeds from the sale of the securities pursuant to the
Registration Statement, and the Company will not obtain any direct
or indirect benefit from any amounts received from those sales. The
only exception being in the event a Selling Shareholder exercises a
warrant on a non-cashless basis.
500
Union St. #810 Seattle WA 98101
Knowlabs.co
The
registration rights granted to the Selling Shareholders are
traditional registration rights and are not indicative of any
present intention of the Selling Shareholders to sell or distribute
the Common Stock, much less sell or distribute the Common Stock on
behalf of the Company. The decision to exercise these registration
rights now and request that the Common Shares be registered with
the Commission was made solely by the contractual obligations
promised to the Selling Shareholders. From the point of view of the
Company, filing the Registration Statement entails significant
legal, accounting and printing costs and filing fees with no
offsetting monetary benefits to the Company. Absent the Selling
Shareholders’ contractual registration rights, the Company
would not be filing the Registration Statement, and the Company
will not receive any proceeds from any subsequent sale of the
Common Shares. The Selling Shareholders negotiated the customary
registration rights set forth for a variety of business reasons,
and, in any case, the registration rights were not granted by the
Company for the purpose of conducting an indirect primary
offering.
The Amount of Shares
Involved
Assuming
all of the 14,337,632 Common Shares being registered for sale by
the Selling Shareholders under the Registration Statement are
issued, on an after-issued basis, they will represent approximately
39% of the total Common Shares outstanding (or approximately 54% of
the total Common Shares outstanding held by non-affiliates) based
on the number of Common Shares outstanding as of June 30,
2019.
The
Company acknowledges the large number of Common Shares involved.
While it appears that the number of Common Shares being registered
is a factor that the Staff considers in its determination regarding
whether an offering should be deemed a primary or secondary
offering, a single-minded focus on the number of securities is
inconsistent with C&DI 612.09 and the facts and circumstances
recited above. As described below, the Staff’s focus on
“toxic” features—which are not a factor in the
proposed offering—is far more likely to deter abusive
practices and uncover disguised primary offerings than a focus on
the number of securities being registered.
We
understand that several years ago the Staff became increasingly
concerned about public resales of securities purchased in
“toxic” transactions. The Staff believed that public
investors often did not have an appropriate understanding as to the
nature of the investment being made or the negative impact that
such transactions could have on the market prices of the shares
involved. In many of these “toxic” transactions, an
issuer would commit to issuing shares at a conversion price that
floated and was subject to change in accordance with the market
price of the underlying common stock. When the deals were
announced, the stock prices typically fell, resulting in the
issuance of significant blocks of stock. In these toxic situations,
existing investors or investors who purchased shares after the
announcement of the transaction frequently faced unrelenting
downward pressure on the value of their investments. In too many of
these cases, the shares held by non-participants in these
transactions were ultimately rendered worthless.
In
order to combat the effects of these toxic transactions, we
understand that the Office of the Chief Counsel and the senior
Staff members of the Commission’s Division of Corporation
Finance began to look at ways to discourage toxic transactions and
to limit the impact of these transactions. One way to do so was to
limit the ability of the investors in those transactions to have
their shares registered.
We
understand that, in order to monitor these types of transactions,
the Staff compared the number of shares an issuer sought to
register with the number of shares outstanding and held by
non-affiliates as disclosed in the issuer’s most recent
Annual Report on Form 10-K. As we understand it, the Staff was
instructed to look more closely at any situation where an offering
involved more than approximately one-third of the public float. If
an issuer sought to register more than one-third of its public
float, the Staff was instructed to examine the transaction to see
if it implicated Staff concerns that a secondary offering might be
a “disguised” primary offering for Rule 415 purposes.
However, according to the Office of the Chief Counsel, the test was
intended to be a mere screening test and was not intended to
substitute for a complete analysis of the factors cited in C&DI
612.09. Moreover, we understand that the Staff’s focus
shifted in late 2006 to “extreme convertible”
transactions to avoid disrupting legitimate PIPE transactions. As
described above, the terms of the Note Offering and Preferred
Offering do not implicate any of the concerns leading to the focus
on extreme convertible situations. There is no danger that public
investors do not have an appropriate understanding as to the nature
of the investment being made or any negative impact on the market
prices of the shares involved, as the Note Offering and Preferred
Offering have been fully disclosed in the Company’s filings
with the Commission.
500
Union St. #810 Seattle WA 98101
Knowlabs.co
Furthermore,
focusing solely on the number of shares being registered in
relation to the shares outstanding or the public float has a
disproportionate impact on the ability of smaller public companies
to utilize the shelf registration process to register shares for
resale, thereby severely limiting their options to raise
funds.
If
the Staff’s concern is that a distribution is taking place,
the number of Shares being registered should be given less weight
in the Staff’s analysis. The availability of Rule 415 depends
on whether the offering is made by Selling Shareholders or deemed
to be made by or on behalf of the issuer. In order for the Staff to
determine that the offering is in fact on behalf of the issuer, by
definition the Staff must conclude that the Selling Shareholders
are seeking to effect a distribution of Shares. Clearly, an illegal
distribution of Shares can take place when the amount of Shares
involved is less than one-third of an issuer’s public float.
In fact, it is far easier to effect an illegal distribution when
the number of Shares involved is relatively small in relation to
the Shares outstanding or the public float. When investors acquire
a large stake of a small public company, particularly one with a
limited trading market like that of the Company, it is virtually
impossible for them to exit their equity position in an orderly
manner through the public markets.
Limiting
the number of Shares being registered does not effect any
significant change in the circumstances of a proposed offering. If
the Selling Shareholders are acting as a mere conduit for the
Company, cutting back on the number of Common Shares being sold
does not change the investment intent of the Selling Shareholders
or the ability of the Selling Shareholders to effect a distribution
if, in fact, that was their intent.
The
Staff’s interpretative position set forth in C&DI 612.12
makes clear that the amount of securities offered, whether by an
affiliate or otherwise, is not the determinative factor when
considering whether an offering is properly characterized as a
primary offering or a secondary offering. Other factors discussed
in this letter, such as the Selling Shareholders’ investment
intent, and the circumstances under which the Selling Shareholders
acquired the securities, support the characterization of the
proposed offering as secondary in nature. C&DI 612.12 describes
a scenario where a holder of well over one-third of the outstanding
stock is able to effect a valid secondary offering. The
interpretation states, in relevant part, that:
A
controlling person of an issuer owns a 73% block. That person will
sell the block in a registered “at-the-market” equity
offering. Rule 415(a)(4) [which places certain limitations on
“at-the-market” equity offerings] applies only to
offerings by or on behalf of the registrant. A secondary offering
by a control person that is not deemed to be by or on behalf of the
registrant is not restricted by Rule 415(a)(4).
In addition, C&DI 216.14, regarding the use of Form S-3 to
effect a secondary offering provides:
Secondary
sales by affiliates may be made under General Instruction I.B.3. to
Form S-3 [relating to secondary offerings], even in cases where the
affiliate owns more than 50% of the issuer’s securities,
unless the facts and circumstances indicate that the affiliate is
acting as an underwriter or by or on behalf of the
issuer.
These interpretive positions support the Company’s belief
that a holder of well in excess of one-third of the public float
can effect a valid secondary offering of its Shares unless other
facts—beyond the mere level of ownership—indicate that
the holder is acting as a conduit for the issuer.
A
focus on the number of shares being registered appears reminiscent
of the “presumptive underwriter” doctrine, under which
the Staff previously took the position that the sale of more than
10% of the outstanding registered stock of an issuer made the
investor a “presumptive underwriter” of the offering.
The Company notes that the presumptive underwriter doctrine was
abandoned by the Staff more than 20 years ago. See American Council
of Life Insurance (avail. June 10, 1983). More recent rule
making has continued this trend away from this doctrine. See
Securities Act Release No. 33-8869 (December 6, 2007)
(eliminating the “presumptive underwriter” provisions
of Rule 145(c) and (d) in most cases). Accordingly, the
Company believes that there is no basis to apply the doctrine
here.
500
Union St. #810 Seattle WA 98101
Knowlabs.co
A
focus solely on numbers of Common Shares to be registered also
ignores a fundamental aspect of these transactions: investors in
PIPEs are funding business plans and strategic initiatives, not
looking to take control of public issuers or to illegally
distribute Shares. In this case, the investors evaluated an
investment in the Company on the basis of the business purpose for
the Note Offering and Preferred Offering and whether they believed
that the Company’s proposed use of proceeds was rational and
likely to produce above average investment returns. By focusing on
the percentage of the public float or the percentage of the Shares
outstanding, the Staff unfairly penalizes smaller companies such as
the Company by disproportionately hindering their ability to raise
desperately-needed capital to execute their business plans and
strategic initiatives. It is difficult to harmonize a focus on the
number of securities being registered by smaller companies with the
Commission’s public commitment to smaller companies.
Furthermore, the enactment of the Jumpstart Our Business Startups
Act demonstrates that Congress is focused on making access to the
capital markets easier, not harder, for smaller public
companies.
Indeed,
as indicated in its periodic reports, the Company’s ability
to grow and develop is technology and products, requires the
completion of financings, such as the one represented by the Note
Offering and Preferred Offering, in a timely manner. Investors like
the Selling Shareholders provide issuers like the Company with the
means to further their business plans and strategic initiatives
and, by extension, to provide returns to all Stockholders. In the
case of the Note Offering and Preferred Offering, the Investors
evaluated an investment in the Company on the basis of the business
purpose for the offering and whether they believed the
Company’s use of proceeds was rational and likely to produce
favorable investment returns. The number of shares that they
purchased was simply a mathematical result of the size of the
investment, the price per unit and the Company’s market
capitalization. PIPE investors do not typically look to acquire a
specific proportion of a company and then calculate an investment
amount based on that desired level of ownership. We respectfully
submit that cutting off the ability to finance the operations of
smaller companies through transactions such as the Private
Placement will create dire consequences for these types of
companies and their investors, with no corresponding benefit from
an investor protection perspective or otherwise.
Whether the Sellers Are in the
Business of Underwriting Securities
Aside
from the Broker-Dealer Parties, who hold warrants received as
compensation for services, none of the Selling Shareholders has an
underwriting relationship with the Company or, to the
Company’s knowledge, is in the business of underwriting
securities. The Selling Shareholders buy and sell securities for
their own accounts and not for the accounts of others. All of the
Selling Shareholders represented at the time of purchase that they
were buying for their own accounts and not with an intention to
distribute in violation of the Securities Act. There is no
allegation that those representations and warranties are untrue and
no factual basis exists for any such allegation. To the
Company’s knowledge, none of the Selling Shareholders has
sold any of the securities being registered since the closing of
the respective offering, nor have any Selling Shareholders
converted the Notes or Preferred shares. In addition, to the
Company’s knowledge, no Selling Shareholders has any
agreements or understandings, directly or indirectly, with any
person to distribute the Common Stock issuable upon conversion of
the Notes or Preferred shares.
Section 2(a)(11)
of the Securities Act defines the term “underwriter” as
“any person who has purchased from an issuer with a view to,
or offers or sells for an issuer in connection with, the
distribution of any security, or participates or has a direct or
indirect participation in any such undertaking, or participates or
has a participation in the direct or indirect underwriting of any
such undertaking….” Each Selling Shareholder has
represented that such Selling Shareholder has purchased the
securities convertible into the Common Shares in the ordinary
course for such Selling Shareholder’s own account and not
with a view toward, or for resale in connection with, the public
sale or distribution thereof, except pursuant to sales registered
under the Securities Act or under an exemption from such
registration and in compliance with applicable federal and state
securities laws, and they do not have a present arrangement to
effect any distribution of the Common Shares registered in the
Registration Statement to or through any person or entity.
Accordingly, the Company believes that none of the characteristics
commonly associated with acting as an underwriter are
present.
500
Union St. #810 Seattle WA 98101
Knowlabs.co
Whether Under All the
Circumstances it appears that the Selling Shareholders are Acting
as a Conduit for the Issuer
As
the facts and analysis provided above demonstrate, the Selling
Shareholders are not engaging in a distribution and are not acting
as conduits for the Company. The Selling Shareholders made
fundamental decisions to invest in the Company, have held their
securities for a period of time that exceeds the periods sanctioned
in the Staff’s C&DIs, and have represented that they
purchased the securities for their own accounts and not with a view
to the resale or distribution thereof, and that they had no present
intention of selling or otherwise distributing such securities. In
addition, each of the Selling Shareholders represented that it had
made its own independent decision to purchase the securities, and
there is no evidence to suggest that any of the Selling
Shareholders are acting in concert to effect a coordinated
distribution of the securities.
None
of the Selling Shareholders are in the business of underwriting
securities and all of the proceeds of the offering of the Common
Shares under the Registration Statement will be retained by the
Selling Shareholders. In these circumstances, the Company believes
that the offering it seeks to register pursuant to the Registration
Statement is a valid secondary offering that should be allowed to
proceed consistent with Rule 415.
Conclusion
For
all of the foregoing reasons, the Company believes that the facts
and circumstances compel the conclusion that the offering pursuant
to the Registration Statement is a valid secondary offering by the
Selling Shareholders eligible to be made on a shelf basis under
Rule 415(a)(1)(i) and that the Company should be permitted to
proceed with the registration of all of the Common Shares issuable
in connection with the conversion of the Notes and Preferred issued
pursuant to the Note Offering and Preferred Offering. No potential
violation of Rule 415 exists and, in these circumstances, there is
no risk to the investing public if the Registration Statement is
declared effective as to all of the Common Shares issuable in
connection with the Private Placement.
8.
Please
include in your response to prior comment 3 information regarding
prior securities transactions between the issuer (or any of its
predecessors) and the Selling Shareholders, any affiliates of the
Selling Shareholders, or any person with whom any Selling
Shareholder has a contractual relationship regarding the
transaction (or any predecessors of those persons). Include the
date of each transaction and the consideration paid, and whether
the securities have since been sold by the Selling Shareholder.
Also clearly identify in your response when you have previously
registered securities for resale by the selling security holders
named in this registration statement, including whether and when
those securities have been sold.
Response. There are no prior
securities transactions between the Company and the selling
shareholders or affiliates or contractual parties thereto with
exception of those following parties and transactions described in
Exhibit C attached hereto and incorporated herein by
reference.
In furtherance to the information provided in Exhibit C, the only
securities set forth therein which have been registered are (i)
1,785,714 shares of common stock issuable upon conversion of the
Series C Redeemable Convertible Preferred Stock and (ii) up to
1,785,714 shares of common stock issuable upon the exercise of
outstanding Series E Warrants. These were registered via Form S-1
as amended by Post Effective Amendment made effective August 21,
2018. No shares have been sold by the Selling Shareholder.
The
9.
Please disclose (1)
the price of your common stock on the dates that the selling
security holders acquired the offered common stock or the
securities by which they can acquire the offered common stock, and
(2) the cash fee paid to the selling security holder. Also: clarify
how the conversion and exercise price adjustments will be made for
events requiring adjustments; and in the context of your disclosure
regarding the Series D Convertible Preferred Stock, disclose the
stated value of that preferred stock.
Response. (1) The Price of the
Company’s common stock on the date the Selling Shareholders
acquired securities
by which they can acquire the offered common stock was as follows:
(i) the offering price of the 8% convertible notes, warrants and
related securities issued between January 31, 2019 and May 2019,
was set at approximately $1.00 per share which was the closing
price of the Company’s common stock as of January 31, 2019
(the date the offering commenced). The average closing stock price
between January 31, 2019 and May 31, 2019 was approximately $1.57,
and (ii) the Series D Preferred Stock and Series F Warrants were
acquired on November 10, 2016 at a stated value of $0.80 per share;
the closing price of the common stock on the date before the
agreement was executed was $1.33 per share.
500
Union St. #810 Seattle WA 98101
Knowlabs.co
(2)
(i)With the exception of the $361,401 fee paid to Boustead
Securities and their affiliates or assign, no cash fee was paid to
the Selling Shareholders owning the 8% convertible notes, warrants
and related securities; (ii) no cash fee has been paid to the
Selling Stockholder owning the Series D Preferred Stock and Series
F Warrants.
(3) The
8% notes and warrants will be adjusted proportionately in the event
of dividends, splits, or other reclassifications. With respect to
the conversion and exercise price adjustments for events requiring
adjustments, pursuant to Section 5(a) of the Series D Preferred
Stock, the conversion price will be adjusted proportionately in the
event of dividends in shares, stock splits, or other
reclassifications, and pursuant to Section 5(b) will be adjusted
downwards to match a conversion, exchange or exercise price per
share offered by the Company to another party which is less than
the Conversion Price of the Series D Preferred immediately in
effect prior to such sale or issuance. The stated value of the
Series D Preferred Stock is currently $0.70 per share.
Please contact me at (206) 903-1351 with any
questions.
Sincerely,
/s/ Ronald P. Erickson
Chairman of the
Board
cc: Kevin Kuhar, Securities and Exchange
Commission
Tim
Buchmiller, Securities and Exchange Commission
Russel
Mancuso, Securities and Exchange Commission
Jessica
M. Lockett, Esq.
500
Union St. #810 Seattle WA 98101
Knowlabs.co
EXHIBIT
A
CALCULATION OF REGISTRATION FEE
(1) In
the event of a stock split, stock dividend or similar transaction
involving our common stock, in order to prevent dilution, the
number of shares registered shall be automatically increased to
cover the additional shares in accordance with Rule 416(a) under
the Securities Act of 1933, as amended (the “Securities
Act”).
(2)
Calculated pursuant to Rule 457(o) based on an estimate of the
proposed maximum aggregate offering price and specifically using
the price at which the warrants may be
exercised.
(3)This
Registration Statement covers the resale by our selling
shareholders (the "Selling Shareholders") of:
(i)up
to 4,242,515 shares of common stock underlying the conversion of
principal amount of registrants 8% Unsubordinated Convertible Notes
(“Principal Shares”)
(ii)up
to 339,402 shares of common stock issuable by the registrant
upon the conversion of interest accrued under the 8%
Unsubordinated Convertible Notes (“Interest Shares”)
(The Principal Shares and Interest Shares are referred to
collectively as the “Shares”).
(iii)
up to 2,121,258 shares (the "Investor Warrant Shares") of common
stock issuable upon the exercise of outstanding investor's warrants
(the "Investor Warrants") at an exercise price of $1.20 that were
previously issued to the Selling Shareholders in connection with 8%
Unsubordinated Convertible Notes offering that closed in a series
of closings between February 15, 2019 and May 28,
2019.
(v) up
to 3,108,356 shares of common stock underlying the outstanding
Series D Convertible Preferred Stock which is convertible at any
time at an initial conversion price of $0.25 per share of our
common stock subject to adjustment for certain events
(“Series D Shares”). There are currently 3,108,356
common shares estimated to underlying the 1,016,004 issued and
outstanding Series D Shares.
(vi) up
to 3,984,000 shares of common stock issuable upon conversion
of outstanding Series F Warrants at an exercise price of $0.25 per
share that were previously issued to one of the Selling
Shareholders in connection with Preferred Stock and Warrant
Purchase Agreement dated November 10, 2016 (“Series F Warrant
Shares”).
(4)
Estimated in accordance with Rule 457(c) of the Securities Act,
solely for the purposes of calculating the registration fee based
upon the average of the high and low prices as reported on the Over
the Counter Bulletin Board ("OTCBB") as of May 29,
2019.
500
Union St. #810 Seattle WA 98101
Knowlabs.co
(5) We are registering 542,102 shares of our common stock issuable
upon the exercise of outstanding placement agent warrants (the
“Placement Agent Warrants”) at an exercise price of
$1.20 per share that were previously issued to Boustead Securities,
LLC and its assigns (collectively “Placement Agent”)
pursuant to an engagement agreement dated November 6, 2018 (the
“Boustead Offering Engagement Agreement”) which
provides that the Placement Agent shall receive that certain number
of warrants to purchase the common stock of the Company equal to
the number of warrants issued under the 8% Unsubordinated
Convertible Note Offering (the “Offering”). In the
event of stock splits, stock dividends or similar transactions
involving the common stock, the number of common shares registered
shall, unless otherwise expressly provided, automatically be deemed
to cover the additional securities to be offered or issued pursuant
to Rule 416 promulgated under the Securities Act of 1933, as
amended (the “Securities Act”). In the event that the
provisions of the agreements require the registrant to issue more
shares than are being registered in this registration statement,
for reasons other than those stated in Rule 416 of the Securities
Act, the registrant will file a new registration statement to
register those additional shares.
500
Union St. #810 Seattle WA 98101
Knowlabs.co
EXHIBIT B
500
Union St. #810 Seattle WA 98101
Knowlabs.co
EXHIBIT
C
Garden State Securities, Inc.
The Company issued the following warrants for the issuance of
common stock to Garden State Securities, Inc. or its employees
related to the Clayton A. Struve transactions detailed
below.
Convertible Promissory Notes, Series C and D Preferred Stock and
related warrants- warrants for the purchase of 837,901 common
shares exercisable at $0.25 per share.
Private placement being registered- warrants for the purchase of
99,000 shares of common stock exercisable at $1.20 per
share.
None of the Garden State Securities, Inc. shares have been
previously registered. On March 28, 2019, 10,610 shares of common
stock were issued to an employee of Garden State Securities, Inc.
related to the exercise of a warrant.
Clayton A. Struve
The Company has engaged in transactions with Mr. Struve, the
Preferred D holder, since approximately 2016. The following is a
summary of transactions with Mr. Struve:
Convertible Promissory Note dated September 30, 2016
On September 30, 2016, the Company entered into a $210,000
Convertible Promissory Note with Clayton A. Struve, an accredited
investor of the Company, to fund short-term working capital. The
Convertible Promissory Note accrued interest at a rate of 10% per
annum and was due on March 30, 2017. The Note holder can convert
the Note into common stock at $0.70 per share. During the year
ended September 30, 2017, the Company recorded interest of $21,000
related to the convertible note. This note was extended in the
Securities Purchase Agreement, General Security Agreement and
Subordination Agreement dated August 14, 2017 with a maturity date
of August 13, 2018. Also, the conversion price of the Debenture was
adjusted to $0.25 per share, subject to certain adjustments. The
balance was increased $75,000 during the year ended September 30,
2018. On November 16, 2018, we signed Amendment 1 to Senior
Secured Convertible Redeemable Notes dated September 30,
2016extending the due dates of the Note to February 27, 2019. On
September 24, 2018, Mr. Struve converted $200,000 of the Note into
800,000 shares of our common stock. The Company recorded accrued interest of $54,671
as of September 30, 2018.
Series C and D Preferred Stock and Warrants
On
August 5, 2016, the Company closed a Series C Preferred Stock and
Warrant Purchase Agreement with Clayton A. Struve, an accredited
investor for the purchase of $1,250,000 of preferred stock with a
conversion price of $0.70 per share. The preferred stock has a
yield of 8% and an ownership blocker of 4.99%. In addition, Mr.
Struve received a five-year warrant to acquire 1,785,714 shares of
common stock at $0.70 per share.
To
determine the effective conversion price, a portion of the proceeds
received by the Company upon issuance of the Series C Preferred
Stock was first allocated to the freestanding warrants issued as
part of this transaction. Given that the warrants will not
subsequently be measured at fair value, the Company determined that
the warrants should receive an allocation of the proceeds based on
their relative fair value. This is based on the understanding that
the FASB staff and the SEC staff believe that a freestanding
instrument issued in a basket transaction should be initially
measured at fair value if it is required to be subsequently
measured at fair value pursuant to US generally accepted accounting
principles (“GAAP”), with the residual proceeds from
the transaction allocated to any remaining instruments based on
their relative fair values. As such, the warrants were allocated a
fair value of approximately $514,706 upon issuance, with the
remaining $735,294 of proceeds allocated to the Series C Preferred
Stock.
Proportionately,
this allocation resulted in approximately 59% of the face amount of
the Series C Preferred Stock issuance remaining, which applied to
the stated conversion price of $0.70 resulted in an effective
conversion price of approximately $0.41.
500
Union St. #810 Seattle WA 98101
Knowlabs.co
Having
determined the effective conversion price, the Company then
compared this to the fair value of the underlying Common Stock as
of the commitment date, which was approximately $1.06 per share,
and concluded that the conversion feature did have an intrinsic
value of $0.65 per share. As such, the Company concluded that the
Series C Preferred Stock did contain a beneficial conversion
feature and an accounting entry and additional financial statement
disclosure was required.
Because
our preferred stock is perpetual, with no stated maturity date, and
the conversions may occur any time from inception, the dividend is
recognized immediately when a beneficial conversion exists at
issuance. During the year ending September 30, 2016, the Company
recognized preferred stock dividends of $1.16 million on Series C
preferred stock related to the beneficial conversion feature
arising from a common stock effective conversion rate of $0.41
versus a current market price of $1.06 per common
share.
On
November 14, 2016, the Company issued 187,500 shares of Series D
Convertible Preferred Stock and a warrant to purchase 187,500
shares of common stock in a private placement to certain accredited
investors for gross proceeds of $150,000 pursuant to a Series D
Preferred Stock and Warrant Purchase Agreement dated November 10,
2016.
The
warrants associated with the November 14, 2016 issuance were
allocated a fair value of approximately $56,539 upon issuance, with
the remaining $63,539 of net proceeds allocated to the Series D
Preferred Stock. Proportionately, this allocation resulted in
approximately 53% of the amount of the Series D Preferred Stock
issuance remaining, which applied to the stated conversion price of
$0.80 resulted in an effective conversion price of approximately
$0.34. Having determined the effective conversion price, the
Company then compared this to the fair value of the underlying
Common Stock as of the commitment date, which was approximately
$1.14 per share, and concluded that the conversion feature did have
an intrinsic value of $0.80 per share. As such, the Company
concluded that the Series D Preferred Stock did contain a
beneficial conversion feature of $150,211 which was recorded as a
beneficial conversion in stockholders’ equity.
On
December 19, 2016, the Company issued 187,500 shares of Series D
Convertible Preferred Stock and a warrant to purchase 187,500
shares of common stock in a private placement to an accredited
investor for gross proceeds of $150,000 pursuant to a Series D
Preferred Stock and Warrant Purchase Agreement dated December 14,
2016.
The
warrants associated with the December 19, 2016 issuance were
allocated a fair value of approximately $60,357 upon issuance, with
the remaining $69,643 of net proceeds allocated to the Series D
Preferred Stock. Proportionately, this allocation resulted in
approximately 54% of the amount of the Series D Preferred Stock
issuance remaining, which applied to the stated conversion price of
$0.80 resulted in an effective conversion price of approximately
$0.37. Having determined the effective conversion price, the
Company then compared this to the fair value of the underlying
Common Stock as of the commitment date, which was approximately
$0.81 per share, and concluded that the conversion feature did have
an intrinsic value of $0.44 per share. As such, the Company
concluded that the Series C Preferred Stock did contain a
beneficial conversion feature of $82,232 which was recorded as a
beneficial conversion in stockholders’ equity.
Because
the Company’s preferred stock is perpetual, with no stated
maturity date, and the conversions may occur any time from
inception, the dividend is recognized immediately when a beneficial
conversion exists at issuance. During the year ending September 30,
2017, the Company recognized preferred stock dividends of $2.3
million on Series D preferred stock related to the beneficial
conversion feature arising from a common stock effective conversion
rate of $0.34 and $0.37 versus the original market price of $1.14
and $1.06 per common share, respectively.
On May 1, 2017, the Company issued 357,143 shares of Series D
Convertible Preferred Stock and a warrant to purchase 357,143
shares of common stock in a private placement to an accredited
investor for gross proceeds of $250,000 pursuant to a Series D
Preferred Stock and Warrant Purchase Agreement dated May 1,
2016.
The initial conversion price of the Series D Shares is $0.70 per
share, subject to certain adjustments. The initial exercise price
of the warrant is $0.70 per share, also subject to certain
adjustments. The Company also amended and restated the Certificate
of Designations, resulting in an adjustment to the conversion price
of all currently outstanding Series D Shares to $0.70 per
share.
500
Union St. #810 Seattle WA 98101
Knowlabs.co
On August 14, 2017, the price of the Series C and D Preferred Stock were
adjusted to $0.25 per share pursuant
to the documents governing such instruments. After adjustment there
were 3,108,356 shares of Series D preferred stock
authorized.
On July
17, 2018, the Company filed with the State of Nevada a second
Amended and Restated Certificate of Designation of Preferences,
Powers, and Rights of the Series D Convertible Preferred Stock. The
Amended Certificate restates the prior Certificate of Designation
filed on May 8, 2017 to decrease the number of authorized Series D
shares from 3,906,250 shares to 1,016,014 shares.
As of June 30, 2019, the Company has 3,108,356 of Series D
Preferred Stock outstanding with Clayton A. Struve, an accredited
investor, outstanding. On August 14,
2017, the price of the Series D
Stock were adjusted to $0.25 per share pursuant to the documents governing such
instruments.
Securities Purchase Agreement dated August 14, 2017
On August 14, 2017, the Company issued a senior convertible
exchangeable debenture with a principal amount of $360,000 and a
common stock purchase warrant to purchase 1,440,000 shares of
common stock in a private placement to Clayton Struve for gross
proceeds of $300,000 pursuant to a Securities Purchase Agreement
dated August 14, 2017. The debenture accrues interest at 20% per
annum and matures August 13, 2018. The convertible debenture
contains a beneficial conversion valued at $110,629. The warrants
were valued at $111,429. Because the note is immediately
convertible, the warrants and beneficial conversion were expensed
as interest.
On the same date, the Company entered into a General Security
Agreement with the Mr. Struve, pursuant to which the Company has
agreed to grant a security interest to the investor in
substantially all of our assets, effective upon the filing of a
UCC-3 termination statement to terminate the security interest held
by Capital Source Business Finance Group in the assets of the
Company. In addition, an entity affiliated with Ronald P. Erickson,
out then Chief Executive Officer, entered into a Subordination
Agreement with the investor pursuant to which all debt owed by us
to such entity is subordinated to amounts owed by us to Mr. Struve
under the Debenture (including amounts that become owing under any
Debentures issued to the investor in the future).
The initial conversion price of the Debenture is $0.25 per share,
subject to certain adjustments. The initial exercise price of the
Warrant is $0.25 per share, also subject to certain
adjustments.
As part of the Purchase Agreement, the Company granted the investor
“piggyback” registration rights to register the shares
of common stock issuable upon the conversion of the Debenture and
the exercise of the Warrant with the Securities and Exchange
Commission for resale or other disposition.
The Debenture and the Warrant were issued in a transaction that was
not registered under the Securities Act of 1933, as amended in
reliance upon applicable exemptions from registration under Section
4(a)(2) of the Act and Rule 506 of SEC Regulation D under the Act.
Under the terms of the Purchase Agreement, Mr. Struve may purchase
up to an aggregate of $1,000,000 principal amount of Debentures
(before a 20% original issue discount) (and Warrants to purchase up
to an aggregate of 250,000 shares of common stock). These
securities are being offered on a “best efforts” basis
by the placement agent.
During the year ended September 30, 2017, $156,941 was recorded as
interest expense related to debt discounts, beneficial conversions
and warrants associated with Convertible Promissory
Notes.
On December 12, 2017, the Company closed an additional $250,000 and
issued a senior convertible exchangeable debenture with a principal
amount of $300,000 and a common stock purchase warrant to purchase
1,200,000 shares of common stock in a private placement dated
December 12, 2017 with Mr. Struve pursuant to a Securities Purchase
Agreement dated August 14, 2017. The convertible debenture contains
a beneficial conversion valued at $93,174. The warrants were valued
at $123,600. Because the note is immediately convertible, the
warrants and beneficial conversion were expensed as
interest.
On March 2, 2018, the Company received gross proceeds of $280,000
in exchange for issuing a senior convertible redeemable debenture
with a principal amount of $336,000 and a warrant to purchase
1,344,000 shares of common stock in a private placement dated
February 28, 2018 with Mr. Struve pursuant to a Securities Purchase
Agreement dated August 14, 2017. The convertible debenture contains
a beneficial conversion valued at $252,932. The warrants were
valued at $348,096. Because the note is immediately convertible,
the warrants and beneficial conversion were expensed as
interest.
500
Union St. #810 Seattle WA 98101
Knowlabs.co
In connection with the February 28, 2018 private placement, the
placement agent for the debenture and the warrant received a cash
fee of $28,000 and the Company issued warrants to purchase shares
of the Company’s common stock to the placement agent or its
affiliates based on 10% of proceeds.
On
November 16, 2018, the Company signed Amendment 1 to Senior Secured
Convertible Redeemable Notes dated August 14, 2017 and December 12,
2017, extending the due dates of the Notes to February 27,
2019.
Convertible Promissory Notes with Clayton A. Struve
As of March 31, 2019, the Company owes Clayton A. Struve $1,071,000
under convertible promissory or OID notes. The Company recorded
accrued interest of $58,411 as of March 31, 2019. On May 8,
2019, the Company signed Amendment 2 to the convertible promissory
or OID notes, extending the due dates to September 30,
2019.
500
Union St. #810 Seattle WA 98101
Knowlabs.co